Roughly 70 percent of medical decisions depend on lab results but lab spending remains one of the least scrutinized lines in a health plan’s budget. That blind spot is getting more expensive.
Routine testing spend is climbing faster than the number of tests ordered and about 10 new genetic tests reach the U.S. market every day. A wave of blood biomarker tests for cancer, minimal residual disease and Alzheimer’s is also arriving faster than the infrastructure to evaluate them.
This report gives payer executives a clear read on where lab spend is heading through 2033 and what separates plans that manage diagnostics actively from those absorbing the cost after the fact.
Inside the report:
- Why lab spend is rising faster than test volume, and what drives it
- How site of service creates wide price variation on identical routine tests
- What the double-digit growth in genetic testing means for spend management